Pharma's Market
SPECIAL REPORT
MOST SHARED
- Solar Market Heating Back Up?
- Realty Execs See Pain Ahead
- Easy Money & Stocks
- Tommy Lee, Medical Tourism and Nasty Santa, Your Emails
- Buying Fear: How to Own Volatility
- Want the Homebuyer's Tax Credit? Here Are Some Tips
- Week Ahead: Stocks Search for Catalyst in Quiet Week
- Video Game Industry's Troubles Aren't Just in US
- Consumers Haven't Changed, They Are Just Pickier
- Tommy Lee, Medical Tourism and Nasty Santa, Your Emails
- U.S. Markets Gain 3% for the Week Despite 10.2% Unemployment
- Disney's 'Carol' Tests Widest 3-D Release Ever
- Stimulus II? Jobs Tax Credit=Cash For Clunkers
- Rockwell Automation Earnings: What Options Are Saying
- Gold Will Touch Higher Lows and Higher Highs: Analyst
- Is Misery Alive And Well in Your Office?
- Consumers Haven't Changed, They Are Just Pickier
- Watch Foreclosures, Seriously
- Week Ahead: Stocks Search for Catalyst in Quiet Week
- Outlook: Dollar Likely to Ride Higher on Bleak Jobs Report
- Health Bill Clears First Hurdle in House
- Buffett's Berkshire Hathaway Says Net Income Tripled
- Cramer: Earnings, IPOs Dominate Next Week
- Buying Fear: How to Own Volatility
- Administration Rejects Plan to Buy Fannie Mae Credits
- Consumers Haven't Changed —They Just Got Pickier
- Want the Homebuyer's Tax Credit? Here Are Some Tips
RSS FEED
Text Size 
Reporter
Today the Food and Drug Administration announced that Pfizer's Chantix [PFE
Loading...
()
] and GlaxoSmithKline's Zyban [GSK
Loading...
()
] will carry new warnings about mental side effects. Not just any old warnings, but so-called "Black Box" warnings. Or, at least, that's what we in the news media used to call them. Until the FDA called us out today.
This is the black box on the Zyban label. It looks pretty much like every other one. It isn't shaded black. It doesn't have a black background with white lettering. It's just a bunch of drug safety-related words doctors and patients should pay attention to that are framed, literally, by a black box. Hence, the term "Black box warning." It's shorthand for the most severe type of warning the FDA can issue. Drugmakers dread it. Investors hate it even more. But, perhaps it will be no more.
On the FDA conference call with reporters this afternoon to discuss the new warnings, two agency officials told the news media to use the phrase "Boxed warning" instead of "Black box warning." Why? As one of them put it, "Black box carries the implication, 'Don't you dare use this'." The other official added, "We don't want to scare people off (from trying to quit smoking). We just want them to be carefully monitored."
The FDA, Pfizer and GSK are all emphasizing what a health burden smoking has become. PFE's Director of Worldwide Communications, Sally Beatty, emailed me to point out that around 70 percent of smokers want to quit, but only three percent are able to do it on willpower alone. On average, she added, smokers try six to nine times in their lifetime to butt out. "We want patients to get the support they need."
When I was growing up my mom was a chain smoker. I hated it. She finally quit cold turkey years after I moved out of the house. But it was too late. She developed kidney cancer, which occurs in cigarette smokers at a much higher rate than non-smokers, and died of metastatic disease.
Chantix sales have already taken a pretty big hit since the reports of mental side effects surfaced about a year-and-a-half ago. And Zyban is a relatively small-selling product for GSK. Sales may shrink even more, though, now that the drugs are getting a new boxed warning. There, you happy FDA? I said it. Boxed is the new black.
Questions? Comments? and follow me on Twitter at mhuckman
Data is a real-time snapshot *Data is delayed at least 15 minutes